KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Income from Continuing Operations (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Income from Continuing Operations data on record, last reported at 25723000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 176.94% year-over-year to 25723000.0; the TTM value through Dec 2025 reached 156122000.0, up 220.57%, while the annual FY2025 figure was 391000000.0, 72.66% up from the prior year.
  • Income from Continuing Operations reached 25723000.0 in Q4 2025 per ACAD's latest filing, down from 71800000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 71800000.0 in Q3 2025 and bottomed at 113085000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 12016750.0, with a median of 20844500.0 recorded in 2021.
  • The widest YoY moves for Income from Continuing Operations: up 2900.81% in 2024, down 173.0% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 43094000.0 in 2021, then increased by 3.29% to 41675000.0 in 2022, then skyrocketed by 209.89% to 45797000.0 in 2023, then crashed by 173.0% to 33431000.0 in 2024, then soared by 176.94% to 25723000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 25723000.0 in Q4 2025, 71800000.0 in Q3 2025, and 40200000.0 in Q2 2025.